Isis Pharma Issues Update on CHMP Opinion on KYNAMRO

Isis Pharmaceuticals Inc.

today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO^TM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia (HoFH). The FDA approved KYNAMRO in the United States in January 2013 for the treatment of patients with Homozygous Familial Hypercholesterolaemia.